Novel agents to target treatment resistance in ovarian cancer

Abstract Chemotherapy resistance is a common occurrence in women who have undergone treatment for epithelial ovarian cancer. Combination chemotherapy, while helpful in delaying the development of resistance, carries increased toxicity and a poorer safety profile. As a result, numerous studies are investigating additional pharmacological targets, combination therapies, and repurposed agents for ovarian cancer treatment. This chapter summarizes clinical studies investigating novel combination therapies and targeted treatments that may hold promise in future clinical applications.